Cinaciguat

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Cinaciguat
Cinaciguat structure.svg
Clinical data
Routes of
administration
intravenous (?)
ATC code
  • none
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
Chemical and physical data
Formula C36H39NO5
Molar mass 565.697 g/mol
3D model (JSmol)
 NYesY (what is this?)  (verify)

Cinaciguat (BAY 58-2667) is an experimental drug for the treatment of acute decompensated heart failure.

Mechanism of action[edit]

Cinaciguat activates the soluble guanylate cyclase (sGC) which is a receptor for nitric oxide. This increases biosynthesis of cyclic GMP, resulting in vasodilation.[1]

See also[edit]

  • Riociguat, another drug stimulating sGC, but with a different mechanism
  • PDE5 inhibitors act further downstream in the nitric oxide signalling pathway, reducing cyclic GMP degradation.

References[edit]

  1. ^ Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel 2009